Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: J Med Chem. 2016 Jun 17;59(13):6136–6148. doi: 10.1021/acs.jmedchem.6b00040

Figure 1.

Figure 1

Structures of FDA-approved INSTIs: raltegravir (1), elvitegravir (2), dolutegravir (3), and our newly designed HPD inhibitor subtype 4. Each approved drug features a chelating traid (red) and a terminal benzyl group (blue) that constitute the pharmacophore of HIV-1 INSTIs. Chemotype 4 fits the pharmacophore with the same two structural features.